$16.26
2.87% day before yesterday
Nasdaq, Sep 06, 10:16 pm CET
ISIN
US0008991046
Symbol
ADMA
Sector
Industry

ADMA Biologics, Inc. Stock price

$16.26
+4.40 37.10% 1M
+10.14 165.69% 6M
+11.74 259.73% YTD
+12.26 306.50% 1Y
+14.93 1,122.56% 3Y
+11.56 245.96% 5Y
+6.41 65.08% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.48 2.87%
ISIN
US0008991046
Symbol
ADMA
Sector
Industry

Key metrics

Market capitalization $3.79b
Enterprise Value $3.84b
P/E (TTM) P/E ratio 115.65
EV/FCF (TTM) EV/FCF 57.67
EV/Sales (TTM) EV/Sales 11.64
P/S ratio (TTM) P/S ratio 11.48
P/B ratio (TTM) P/B ratio 20.13
Revenue growth (TTM) Revenue growth 58.69%
Revenue (TTM) Revenue $330.24m
EBIT (operating result TTM) EBIT $83.94m
Free Cash Flow (TTM) Free Cash Flow $66.64m
Cash position $88.24m
EPS (TTM) EPS $0.14
P/E forward 33.88
P/S forward 9.34
EV/Sales forward 9.47
Short interest 3.98%
Show more

Is ADMA Biologics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

ADMA Biologics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a ADMA Biologics, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a ADMA Biologics, Inc. forecast:

Buy
100%

Financial data from ADMA Biologics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
330 330
59% 59%
100%
- Direct Costs 179 179
18% 18%
54%
152 152
169% 169%
46%
- Selling and Administrative Expenses 57 57
6% 6%
17%
- Research and Development Expense 2.05 2.05
53% 53%
1%
92 92
1,157% 1,157%
28%
- Depreciation and Amortization 8.36 8.36
5% 5%
3%
EBIT (Operating Income) EBIT 84 84
604% 604%
25%
Net Profit 35 35
186% 186%
11%

In millions USD.

Don't miss a Thing! We will send you all news about ADMA Biologics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ADMA Biologics, Inc. Stock News

Positive
Investors Business Daily
22 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
Seeking Alpha
30 days ago
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and CEO Brad Tade - Vice President, Financial Operations Conference Call Participants Anthony Petrone - Mizuho Americas Rick Miller - Cantor Fitzgerald Gary Nachman - Raymond Jame...
Neutral
GlobeNewsWire
about one month ago
RAMSEY, N.J. and BOCA RATON, Fla.
More ADMA Biologics, Inc. News

Company Profile

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.

Head office United States
CEO Adam Grossman
Employees 624
Founded 2004
Website www.admabiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today